Y-Intercept (HK)’s CorMedix CRMD Stock Holding History

Y-Intercept (HK)’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-130,244	Closed	-$1.51M	–	1623
2025 Q3	$1.51M	Buy	+130,244	New	+$1.57M	0.04%	772

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Y-Intercept (HK)'s CRMD Position: Q4 2025 in Review

Y-Intercept (HK) sold out of CorMedix (CRMD) in Q4 2025, closing a stake of 130,244 shares — an estimated $1.51M sold.

Y-Intercept (HK) first reported a position in CRMD in Q3 2025 and held it in 1 quarter. The position peaked at $1.51M in Q3 2025. 198 funds tracked by Wall St. Rank hold CRMD as of Q4 2025.

Y-Intercept (HK) reported no remaining CorMedix position as of Q4 2025 after selling out during the quarter.
Y-Intercept (HK) sold 130,244 CorMedix shares in Q4 2025, an estimated $1.51M.
Y-Intercept (HK) first reported a position in CorMedix in Q3 2025 and held it in 1 quarter.
Y-Intercept (HK)'s CorMedix position peaked at $1.51M in Q3 2025.
198 funds tracked by Wall St. Rank held CorMedix as of Q4 2025.

Based on Y-Intercept (HK)'s 13F filing for Q4 2025, filed 13 Feb 2026.